Next-Generation Sequencing Market – Industry Structure Evaluation, Demand Drivers Analysis, Regional Growth Analysis and Identification, Competitive Positioning Review & Global Market Size Forecast to 2032

22.2%
CAGR (2026-2032)
25.7 USD Bn.
Forecast Market Size
318
Report Pages
141
Market Tables

Overview

The Next-Generation Sequencing Market size was valued at USD 25.7 Billion in 2025 and the total Next-Generation Sequencing revenue is expected to grow at a CAGR of 22.2% from 2025 to 2032, reaching nearly USD 104.57 Billion.

Next-Generation Sequencing Market Overview

The next-generation sequencing (NGS) market is a rapidly growing sector within the genomics industry, driven by advancements in sequencing technologies, reducing costs, and increasing demand for precision medicine. NGS allows for faster and more accurate DNA sequencing, enabling a wide range of applications, including personalized medicine, genetic testing, oncology research, and infectious disease diagnostics. The market is witnessing significant growth due to its ability to provide high-throughput, cost-effective solutions compared to traditional sequencing methods. Key drivers include the rise in cancer and genetic disorders, advancements in bioinformatics, and the increasing adoption of NGS in research and clinical diagnostics. Major players in the market are focusing on enhancing sequencing platforms, improving data analysis software, and expanding their service offerings to cater to a diverse clientele. As healthcare and research institutions prioritize precision medicine, the NGS market is poised to continue its upward trajectory in the coming years.

To know about the Research Methodology:- Request Free Sample Report

Global Next-Generation Sequencing Market Overview:

Next-generation sequencing is also known as high-throughput sequencing because it encompasses a variety of advanced sequencing technologies. These new technologies have changed the study of genomics and molecular biology by enabling DNA and RNA to be produced more cheaply, quickly, and without creating as much cost as conventional technologies. The sequential counting of nucleotides to immobilized and spatially arrayed RNA or DNA templates is screened using this next-generation sequencing (NGS) technology. However, there are significant differences between how these RNA or DNA templates are created and how they are interrogated to reveal their sequences. As a result, next-generation sequencing has filled in the holes to meet these higher-level understanding requirements and has become a popular analysis method. The scalability of next-generation sequencing allows for changing the level of precision to satisfy laboratory needs, making it a digital alternative to sequence-based gene expression.

Global Next-Generation Sequencing Market

Drivers:

One of the main factors driving the market's growth is the rising prevalence of chronic medical conditions such as cancer, as well as numerous technical advances in the field of medical sciences. There has been substantial growth in the use of NGS technology as a result of the widespread use of liquid biopsies in cancer diagnostics. Continuous technical advancements in sequencers have allowed the development of reliable, compact, and simple-to-use NGS platforms that can provide fast and accurate results while also reducing turnaround times. The launch of such products and the technology that underpins them gives players an instant competitive advantage; as a result, major corporations are continually relying on product research and development to improve their market positions and share.

Furthermore, the growing use of genome mapping programs to predict the onset of various diseases is fueling the market growth. Scientists use genetic maps to help them figure out which genes are linked to rising rates of diabetes, heart disease, obesity, cancer, and mental disorders. Moreover, numerous technology advances and convergence of cloud-computing platforms for better data processing are positively impacting the market growth. Other trends, such as falling NGS system costs and robust research and development (R&D) activities in the fields of sequencing chemistry, molecular biology, and technological engineering, are expected to fuel the global next-generation sequencing market even more. Other trends, such as falling NGS system costs and robust research and development (R&D) activities in the fields of sequencing chemistry, molecular biology, and technological engineering, are expected to fuel the global next-generation sequencing market even more.

Restraints:

Academic R&D in developed countries is largely reliant on outside finance. Despite government and private sector initiatives to provide funding for research around the world, numerous scientific and university institutes are experiencing budget pressures when it comes to the procurement and usage of sophisticated and high-priced equipment and technology. As a consequence, advanced research facility construction and extension in university and research institutes in developed countries are slowed. This is a major impediment to the implementation of innovations like NGS in developed countries in Africa and Asia.

Global Next-Generation Sequencing Market Segment Analysis:

Based on Technology, Whole Genome Sequencing (WGS) and Whole Exome Sequencing (WES) are the dominant technologies. WGS offers comprehensive analysis by sequencing the entire genome, making it invaluable for applications such as rare disease research, personalized medicine, and oncology. It allows for a deeper understanding of genetic variations that influence health outcomes. WES, while not as exhaustive as WGS, focuses on sequencing the exons, the protein-coding regions of the genome, which comprise about 1-2% of the genome but are known to harbor the majority of clinically relevant variants. WES is widely used in both clinical diagnostics and research due to its ability to identify key genetic mutations associated with diseases like cancer and inherited conditions, offering a cost-effective alternative to WGS.

Based on End User, Academic research institutions held the largest share for the Next-Generation Sequencing Market in 2025. The users of NGS technology are leveraging it for cutting-edge genomic studies, biomarker discovery, and disease pathogenesis understanding. Clinical research also plays a vital role, particularly in the development of precision medicine. Clinical applications, including genetic diagnostics and targeted therapies, are growing rapidly, making clinical research a significant contributor to the NGS market's expansion. Both sectors drive innovation and the adoption of NGS technology, influencing its continued evolution.

Global Next-Generation Sequencing Market Regional Insights:

The North American Next-Generation Sequencing (NGS) market is one of the largest and fastest-growing regions globally, driven by strong healthcare infrastructure, technological advancements, and significant investments in genomics research. The market in this region is primarily fueled by the increasing adoption of precision medicine, rising awareness of genetic diseases, and advancements in biotechnology. The United States holds a dominant position, with major players like Illumina, Thermo Fisher Scientific, and PacBio leading the development of sequencing technologies and platforms. The availability of government funding, along with collaborations between academic institutions, healthcare providers, and pharmaceutical companies, further strengthens the growth of the NGS market in North America.

In addition to its role in clinical diagnostics, NGS is widely used in research areas such as cancer genomics, infectious diseases, and rare genetic disorders, contributing to a surge in demand for sequencing services. The adoption of NGS by hospitals, clinics, and pharmaceutical entities for personalized medicine and drug discovery is expanding rapidly. Moreover, advancements in bioinformatics and data analytics are enhancing the interpretation of NGS data, making it more accessible for clinical and academic purposes. As North America continues to lead in genomic research, the NGS market is expected to maintain robust growth in the coming years.

Recent Developments:

In 2026, Agilent continued strengthening its NGS portfolio by enhancing its target enrichment and library preparation reagents, notably the SureSelect and Avida systems that improve genomic region capture and sequence quality for both research and clinical workflows. Their chemistry‑driven solutions aim to optimize sample preparation and integration with automation and QC platforms, helping laboratories improve accuracy and throughput in targeted sequencing applications. Agilent’s focus remains on seamless end‑to‑end NGS workflows by integrating advanced enrichment, sample‑to‑result solutions, and quality controls, supporting growing demand for high‑performance sequencing in oncology, rare disease research, and personalized medicine.

In 2025,  Azenta Inc.: Azenta has been expanding its genomic services business, including NGS sample management, automation solutions, and sequencing services that cater to large‑scale studies. In recent updates, the company emphasized its enhanced biorepository and genomic storage capabilities, improving sample integrity and traceability for high‑volume genomics pipelines. Azenta’s systems are increasingly adopted by pharmaceutical and academic researchers aiming to scale sequencing projects with reliable sample workflows.

Global Next-Generation Sequencing Market Scope: Inquire before buying

Next-Generation Sequencing Market
Report Coverage Details
Base Year: 2025 Forecast Period: 2026-2032
Historical Data: 2020 to 2025 Market Size in 2025: 25.7 USD Billion
Forecast Period 2026-2032 CAGR: 22.2% Market Size in 2032: 104.57 USD Billion
Segments Covered: by Technology WGS (Whole Genome Sequencing)
Whole Exome Sequencing
Targeted Sequencing & Resequencing
    DNA-based
    RNA-based
Others
by Product Platform
    Sequencing
    Data Analysis
Consumables
    Sample Preparation
    Target Enrichment
    Others
by Application Oncology
    Diagnostics and Screening
        Oncology Screening
            Sporadic Cancer
            Inherited Cancer
        Companion Diagnostics
        Other Diagnostics
    Research Studies
Clinical Investigation
    Infectious Diseases
    Inherited Diseases
    Idiopathic Diseases
    Non-Communicable/Other Diseases
Reproductive Health
    NIPT
            Aneuploidy
            Microdeletions
    PGT
    Newborn Genetic Screening
    Single Gene Analysis
    HLA Typing/Immune System Monitoring
    Metagenomics, Epidemiology & Drug Development
    Agrigenomics & Forensics
    Consumer Genomics
by Workflow Pre-Sequencing
    Nucleic Acid Extraction
    Library Preparation
Sequencing
NGS Data Analysis
    NGS Primary Data Analysis
    NGS Secondary Data Analysis
    NGS Tertiary Data Analysis
by End Use Academic Research
Clinical Research
Hospitals & Clinics
Pharma & Biotech Entities
Other

Global Next-Generation Sequencing Market, by Region

North America (United States, Canada, Mexico)
Europe (United Kingdom, France, Germany, Italy, Spain, Sweden, Russia, Poland, Belgium, Netherlands, Rest of Europe)
Asia Pacific (China, South Korea, India, Japan, Australia, Indonesia, Malaysia, Philippines, Thailand, Vietnam, Rest of Asia Pacific)
Middle East & Africa (South Africa, GCC, Egypt, Nigeria, Rest of MEA)
South America (Brazil, Argentina, Colombia, Chile, Rest of South America)

Key players/Competitors profiles covered in the Next-Generation Sequencing  Market report in a strategic perspective

  1. Agilent Technologies Inc.
  2. Azenta Inc.
  3. BGI Genomics Co. Ltd.
  4. 10X Genomics Inc.
  5. Bio Rad Laboratories Inc.
  6. Element Biosciences Inc.
  7. Eurofins Scientific SE
  8. Hoffman-La Roche Ltd
  9. Fluidigm
  10. Fulgent Genetics Inc.
  11. Guardant Health Inc.
  12. Illumina Inc.
  13. Konica Minolta Inc.
  14. Laboratory Corp. of America Holdings
  15. Macrogen Inc.
  16. Merck KGaA
  17. MilliporeSigma
  18. Mission Bio, Inc.
  19. Nabsys Inc.
  20. NanoString Technologies
  21. New England Biolabs, Inc.
  22. OPKO Health Inc.
  23. PacBio
  24. PierianDx Inc.
  25. Promega Corporation
  26. Psomagen Inc.
  27. Qiagen N.V.
  28. Singular Genomics Systems Inc.
  29. Standard BioTools Inc.
  30. Takara Bio Inc.
  31. Thermo Fisher Scientific, Inc.
  32. Twist Bioscience Corp.

Table of Contents

1. Next-Generation Sequencing Market : Market Introduction 1.1. Executive Summary 1.2. Market Size (2025) & Forecast (2026-2032), 1.3. Market Size (USD Million) and Market Share (%) - By Segments, Regions and Country 2. Competitive Landscape 2.1. MMR Competition Matrix 2.2. Competitive Analysis of key players 2.3. Key Players Benchmarking 2.3.1 Company Name 2.3.2 Headquarters 2.3.3 Business Segments 2.3.4 Market Share (%) 2.3.5 Revenue (USD Million) – 2025 2.3.6 Growth Rate (%) 2.3.7 R&D Investment (% of Revenue) 2.3.8 Gross & Operating Margin (%) 2.3.9 Platform Accuracy and Sequencing Depth Capability 2.3.10 Bioinformatics and Data Analysis Strength 2.3.11 Automation Level in Sample Processing Systems 2.3.12 Integration with Clinical and Research Platforms 2.3.13 Scalability Across High-Throughput Laboratories 2.3.14 Recent Developments and Product Launches 2.3.15 Geographical Presence 2.3.16 Strategic Partnerships & Alliances 2.4. Market Structure 2.4.1 Market Leaders 2.4.2 Market Followers 2.4.3 Emerging Players 2.5. Strategic Positioning & Core Strength Assessment 2.5.1 Breadth of next-generation sequencing portfolio 2.5.2 Strength in platform accuracy and reliability 2.5.3 Scalability for high-volume sequencing projects 2.5.4 Integration with laboratory automation systems 2.5.5 Service and support network across regions 2.5.6 Customer retention and long-term partnerships 2.6. Strategic Initiatives and Investment Activities 2.6.1 Mergers and acquisitions among sequencing vendors 2.6.2 Venture funding in genomics start-ups 2.6.3 Expansion into clinical diagnostic markets 2.6.4 Launch of new sequencing chemistries 2.6.5 Partnerships with pharmaceutical organizations 2.6.6 Geographic expansion into developing economies 3. Next-Generation Sequencing Market Dynamics 3.1. Next-Generation Sequencing Market Trends 3.2. Next-Generation Sequencing Market Dynamics 3.2.1 Drivers 3.2.2 Restraints 3.2.3 Opportunities 3.2.4 Challenges 3.3. PORTER’s Five Forces Analysis 3.4. PESTLE Analysis 4. Technology Architecture & Capability Benchmarking 4.1 Comparative analysis of WGS and targeted sequencing 4.2 Performance benchmarking of short-read technologies 4.3 Advances in long-read sequencing platforms 4.4 Accuracy and coverage comparison across methods 4.5 Automation in library preparation workflows 4.6 Integration of AI in sequencing analytics 4.7 Turnaround time optimization across technologies 5. Pricing, Cost Structure & Profitability Analysis 5.1 Pricing models for sequencing platforms globally 5.2 Cost breakdown of consumables and reagents 5.3 Service pricing for outsourced sequencing 5.4 Impact of throughput on overall cost 5.5 Margin analysis across vendor categories 5.6 Total cost of ownership considerations 5.7 Regional pricing variations and trends 6. Data Management & Integration Analysis 6.1 Integration with laboratory information systems 6.2 Bioinformatics infrastructure requirements 6.3 Data storage and cloud computing needs 6.4 Security and encryption of genomic data 6.5 Interoperability across analytics platforms 6.6 Real-time data sharing across institutions 6.7 Compliance with healthcare data standards 7. Deployment Models & Platform Strategies 7.1 Standalone sequencing platforms vs integrated labs 7.2 Cloud-based bioinformatics solution adoption 7.3 Modular workflow implementation approaches 7.4 On-premise versus cloud deployment models 7.5 Vendor lock-in and migration challenges 7.6 Custom bioinformatics pipeline development 7.7 Implementation timelines and scalability 8. End-User Adoption & Demand Behavior Analysis 8.1 Adoption trends in academic research institutes 8.2 Demand from pharmaceutical research divisions 8.3 Hospital and clinical laboratory utilization 8.4 CRO and diagnostic lab requirements 8.5 Government-funded genomics initiatives 8.6 Buyer decision criteria across segments 8.7 Regional differences in technology adoption 9. Reliability, Security & Lifecycle Assessment 9.1 Quality assurance in sequencing workflows 9.2 Data privacy regulations and compliance 9.3 Reliability of clinical-grade sequencing 9.4 Auditability of genomic data processes 9.5 Lifecycle management of sequencing platforms 9.6 Ethical considerations in genetic testing 9.7 Bias mitigation in bioinformatics algorithms 10. Aftermarket, Support & Lifecycle Economics 10.1 Maintenance and service contract models 10.2 Consumables replacement cycle economics 10.3 Platform upgrade and refresh strategies 10.4 Training and technical support services 10.5 Customer retention and renewal trends 10.6 Add-on module revenue opportunities 10.7 Long-term operational cost optimization 11. Regional Infrastructure & Readiness Assessment 11.1 North America sequencing market maturity 11.2 European regulatory and adoption landscape 11.3 Asia-Pacific genomics infrastructure growth 11.4 Middle East research funding initiatives 11.5 Latin America market development potential 11.6 Localization of sequencing technologies 11.7 Talent availability across global regions 12. Impact of Generative AI on Sequencing 12.1 AI-driven variant calling and interpretation 12.2 Automation in genomic data processing 12.3 Machine learning in disease prediction 12.4 AI-enabled precision oncology solutions 12.5 Predictive analytics for drug discovery 12.6 Integration of AI with clinical genomics 13. Industry Consolidation & Vendor Landscape 13.1 Consolidation trends among sequencing providers 13.2 Entry of large diagnostics corporations 13.3 Competitive pressure from new technologies 13.4 Role of start-ups in innovation 13.5 Vendor switching dynamics in laboratories 13.6 Future market share movement predictions 14. Policy Framework & Regulatory Impact 14.1 AFDA and EMA regulatory pathways 14.2 Data protection laws in genomics 14.3 Reimbursement policies for diagnostics 14.4 Ethical frameworks for genetic testing 14.5 International compliance requirements 14.6 Cross-border data transfer regulations 15. Next-Generation Sequencing Market Case Studies 15.1 Oncology diagnostics sequencing implementation case 15.2 Hospital genomics center deployment example 15.3 Infectious disease outbreak sequencing case 15.4 Rare disease diagnosis success story 15.5 Population genomics national project example 15.6 Cost reduction via workflow automation 16. Investment, Growth Opportunities & Strategic Roadmap 16.1 High-growth application segments in genomics 16.2 Emerging opportunities in precision medicine 16.3 Expansion potential in developing regions 16.4 Strategic roadmap for new market entrants 16.5 Venture capital trends in sequencing 16.6 Long-term monetization opportunities 17. Cross-Border Deployment & Global Delivery Models 17.1 Multinational sequencing project execution 17.2 Localization of genomic workflows 17.3 Global talent collaboration models 17.4 Data sovereignty in genomics research 17.5 Centralized vs decentralized sequencing 17.6 Support models for international clients 18. Integration with Emerging Healthcare Technologies 18.1 Integration with digital pathology systems 18.2 Linkage with electronic health records 18.3 Role of sequencing in drug discovery 18.4 AI-enabled clinical decision support 18.5 Interoperability with diagnostic platforms 18.6 Future of automated precision healthcare 19. Global Next-Generation Sequencing Market :Size and Forecast By Segmentation (By Value in USD Million) (2025-2032) 19.1. Global Next-Generation Sequencing Market Size and Forecast, By Technology 19.1.1 WGS 19.1.2 Whole Exome Sequencing 19.1.3 Targeted Sequencing & Resequencing 19.1.4 DNA-based 19.1.5 RNA-based 19.1.6 Others 19.2. Global Next-Generation Sequencing Market Size and Forecast, By Product 19.2.1 Platform 19.2.2 Sequencing 19.2.3 Data Analysis 19.2.4 Consumables 19.2.5 Sample Preparation 19.2.6 Target Enrichment 19.2.7 Others 19.3. Global Next-Generation Sequencing Market Size and Forecast, By Application 19.3.1 Oncology 19.3.2 Diagnostics and Screening 19.3.3 Oncology Screening 19.3.4 Sporadic Cancer 19.3.5 Inherited Cancer 19.3.6 Companion Diagnostics 19.3.7 Other Diagnostics 19.3.8 Research Studies 19.3.9 Clinical Investigation 19.3.10 Infectious Diseases 19.3.11 Inherited Diseases 19.3.12 Idiopathic Diseases 19.3.13 Non-Communicable/Other Diseases 19.3.14 Reproductive Health 19.3.15 NIPT 19.3.16 Aneuploidy 19.3.17 Microdeletions 19.3.18 PGT 19.3.19 Newborn Genetic Screening 19.3.20 Single Gene Analysis 19.3.21 HLA Typing/Immune System Monitoring 19.3.22 Metagenomics, Epidemiology & Drug Development 19.3.23 Agrigenomics & Forensics 19.3.24 Consumer Genomics 19.4. Global Next-Generation Sequencing Market Size and Forecast, By Workflow 19.4.1 Pre-Sequencing 19.4.2 Nucleic Acid Extraction 19.4.3 Library Preparation 19.4.4 Sequencing 19.4.5 NGS Data Analysis 19.4.6 NGS Primary Data Analysis 19.4.7 NGS Secondary Data Analysis 19.4.8 NGS Tertiary Data Analysis 19.5. Global Next-Generation Sequencing Market Size and Forecast, By End Use 19.5.1 Academic Research 19.5.2 Clinical Research 19.5.3 Hospitals & Clinics 19.5.4 Pharma & Biotech Entities 19.5.5 Other 19.6. Global Next-Generation Sequencing Market Size and Forecast, By Region 19.6.1 North America 19.6.2 Europe 19.6.3 Asia Pacific 19.6.4 Middle East and Africa 19.6.5 South America 20. North America Next-Generation Sequencing Market Size and Forecast By Segmentation (By Value USD Million) (2025-2032) 20.1. North America Market Size and Forecast, By Technology 20.2. North America Market Size and Forecast, By Product 20.3. North America Market Size and Forecast, By Application 20.4. North America Market Size and Forecast, By Workflow 20.5. North America Market Size and Forecast, By End Use 20.6. North America Market Size and Forecast, By Country 20.6.1 United States 20.6.2 United States Market Size and Forecast, By Technology 20.6.3 United States Market Size and Forecast, By Product 20.6.4 United States Market Size and Forecast, By Application 20.6.5 United States Market Size and Forecast, By Workflow 20.6.6 United States Market Size and Forecast, by End Use 20.6.7 Canada 20.6.8 Mexico 21. Europe Next-Generation Sequencing Market Size and Forecast By Segmentation (By Value USD Million) (2025-2032) 21.1. Europe Market Size and Forecast, By Technology 21.2. Europe Market Size and Forecast, By Product 21.3. Europe Market Size and Forecast, By Application 21.4. Europe Market Size and Forecast, By Workflow 21.5. Europe Market Size and Forecast, By End Use 21.6. Europe Market Size and Forecast, By Country 21.6.1 United Kingdom 21.6.2 France 21.6.3 Germany 21.6.4 Italy 21.6.5 Spain 21.6.6 Sweden 21.6.7 Russia 21.6.8 Rest of Europe 22. Asia Pacific Next-Generation Sequencing Market Size and Forecast By Segmentation (By Value USD Million) (2025-2032) 22.1. Asia Pacific Market Size and Forecast, By Technology 22.2. Asia Pacific Market Size and Forecast, By Product 22.3. Asia Pacific Market Size and Forecast, By Application 22.4. Asia Pacific Market Size and Forecast, By Workflow 22.5. Asia Pacific Market Size and Forecast, By End Use 22.6. Asia Pacific Market Size and Forecast, By Country 22.6.1 China 22.6.2 Japan 22.6.3 South Korea 22.6.4 India 22.6.5 Australia 22.6.6 Malaysia 22.6.7 Thailand 22.6.8 Vietnam 22.6.9 Indonesia 22.6.10 Philippines 22.6.11 Rest of Asia Pacific 23. Middle East and Africa Next-Generation Sequencing Market Size and Forecast By Segmentation (By Value USD Million) (2025-2032) 23.1. Middle East and Africa Market Size and Forecast, By Technology 23.2. Middle East and Africa Market Size and Forecast, By Product 23.3. Middle East and Africa Market Size and Forecast, By Application 23.4. Middle East and Africa Market Size and Forecast, By Workflow 23.5. Middle East and Africa Market Size and Forecast, By End Use 23.6. Middle East and Africa Market Size and Forecast, By Country 23.6.1 South Africa 23.6.2 GCC 23.6.3 Nigeria 23.6.4 Egypt 23.6.5 Turkey 23.6.6 Rest of ME&A 24. South America Next-Generation Sequencing Market Size and Forecast By Segmentation (By Value USD Million) (2025-2032) 24.1. South America Market Size and Forecast, By Technology 24.2. South America Market Size and Forecast, By Product 24.3. South America Market Size and Forecast, By Application 24.4. South America Market Size and Forecast, By Workflow 24.5. South America Market Size and Forecast, By End Use 24.6. South America Market Size and Forecast, By Country 24.6.1 Brazil 24.6.2 Argentina Colombia 24.6.3 Chile 24.6.4 Peru 24.6.5 Rest Of South America 25. Company Profile: Key Players 25.1. Agilent Technologies Inc. 25.1.1 Overview 25.1.2 Business Portfolio 25.1.3 Financial Overview 25.1.4 SWOT Analysis 25.1.5 Strategic Analysis 25.1.6 Recent Developments 25.2. Azenta Inc. 25.3. BGI Genomics Co. Ltd. 25.4. 10X Genomics Inc. 25.5. Bio Rad Laboratories Inc. 25.6. Element Biosciences Inc. 25.7. Eurofins Scientific SE 25.8. F. Hoffman-La Roche Ltd 25.9. Fluidigm 25.10.Fulgent Genetics Inc. 25.11.Guardant Health Inc. 25.12.Illumina Inc. 25.13.Konica Minolta Inc. 25.14.Laboratory Corp. of America Holdings 25.15.Macrogen Inc. 25.16.Merck KGaA 25.17.MilliporeSigma 25.18.Mission Bio, Inc. 25.19.Nabsys Inc. 25.20.NanoString Technologies 25.21.New England Biolabs, Inc. 25.22.OPKO Health Inc. 25.23.PacBio 25.24.PierianDx Inc. 25.25.Promega Corporation 25.26.Psomagen Inc. 25.27.Qiagen N.V. 25.28.Singular Genomics Systems Inc. 25.29.Standard BioTools Inc. 25.30.Takara Bio Inc. 25.31.Thermo Fisher Scientific, Inc. 25.32.Twist Bioscience Corp. 25.32.1 Others Key Players 26. Key Findings 27. Strategic Recommendations 28. Global Next-Generation Sequencing Market : Research Methodology

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Request Customization Download Sample